Coherus Is Confident After US Ranibizumab Filing
Targeting Around 10% Share On Adalimumab
Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.
